Abstract e open prospective combined cytogenetic and clinical study investigated the impact of biological therapy Rituximab on number and structure of chromosomes in Rheumatoid arthritis patients.
Introduction
Rheumatoid arthritis (RA) is a chronic systemic autoimmune infl ammatory disease that aff ect approximately ,  of the adult population and leads to irreversible joint destruction and permanent disability. The etiology of RA is still unknown, but new bio-tech therapies provide significant efficiacy and safety. The evaluative disease activity requires intensive treatment with disease-modifying anti rheumatic drugs (DMARDs) including biological therapy for rheumatoid arthritis. Rituximab is a genetically engineered human/mouse chimerical novel anti-CD monoclonal antibody that selectively binds to C+ pre-B and mature B lymphocytes () causing the profound and prolonged depletion of peripheral-blood B cell subpopulation (, ) . B lymphocytes play central role in the pathogenesis of Rheumatoid arthritis and in secretion of auto antibodies. e fi nal impact of such depletion is the signifi cant decrease of rheumatoid factor and other disease activity parameters in a patient serum. Methotrexate is standard care for RA, but as well as other cytotoxic drugs have many adverse events and may provoke malignancy, malignant lymphomas and tumor lysis syndrome. e purpose of this study and primary goal was to investigate the impact of Rituximab on the number and structure of chromosomes in rheumatoid arthritis patients () . The open-label prospective combined cytogenetic and clinical study was conducted. The secondary aim was to observe the eff ect of cytotoxic therapy Methotrexate on the same chromosomes.
Materials and Methods
A total of  seropositive Rheumatoid arthritis patients,  females and  males, were analyzed for primary end point of eventual cytogenetic eff ects of rituximab. Average age of females was , years and for males , years with total average of  years. e open-label clinical randomized prospective study was conducted. e assessment was done before application of infusion and  month later retrospectively, actually  weeks after the administration of full course of rituximab in infusion. All patients were randomly assigned to receive infusion of rituximab in a full dose of , grams divided in two doses of , gram on Days  and  (,) . e lymphocytes from peripheral blood were cultured according to Moorhead method () . e  millilitres of heparinised blood was taken from RA patients and poured into  ml of RPMI- medium and ml of fetal calf sera infi ltrate with a certain concentration of Penicillin and Streptomycin. A mytogen stimulator Phittohaemaglutinin in adequate concentration was added. After  hours of culture in thermostat at  ºC, Colcemid was added in adequate concentration for controlling the culture for  minutes. en, the culture was poured into glass containers for centrifugation at  spins for  minutes. Supernatant was taken out using Pasteur pipette and replaced by , mol/dm KCl as hypotonic for further  minutes. Centrifugation at  spins and pouring out the supernatant was done again, after that the fi xation (methanol : glace acetic acid ) was added to the culture and left for another  minutes.
is method of fi xation was repeated at least twice, the material was fixed on slides and then collared by Giemsa. For each patient  mitotic cells were analyzed for structural or numeric changes of chromosomes () .
e following table shows patient number, sex, average age and number of smokers. All seropositive RA patients had severe deformative and active disease. Disease activity score (DAS) was , that indicites high disease activity. ey were previously treated with DMARDs, including gold, hydroxychloroquine, lefl unomide, sulfasalazine that were discontinued due to lack of effi ciacy and cytotoxic therapy with methotrexate was prescribed to all.
Results

Genetically fi ndings:
No chromosomal abnormalities in terms of their number and structure were found on all Rheumatoid arthritis patients who received the full course of Rituximab therapy.
In one female patient, who was on longstanding Methotrexate therapy, the first analysis done before the rituximab therapy has shown some initiation of chromosomal aberration. After discontinuation of Methotrexate from therapy, and two weeks after application of Rituximab, those chromosomal initial aberrations disappeared. And normal karyogram was observed.
e Figure  . and . shows karyogram of this patient. 
Discussion
All  patients who received biological therapy with Rituximab showed no either numerical or structural changes of their chromosomes. What so ever, one female RA patients who was treated with cytotoxic agent Methotrexate showed initially some chromosomal aberration, but after excluding this drug from treatment and introduction of Rituximab in a therapy, the normal karyogram was found.
Metotrexate
No similar study on chromosomes was done so far, so our data could not be comparable. Other authors evaluated safety profile in many open-label extension studies and also in double-blind prospective randomized ones. The incidence of malignancies after rituximab therapy was , per  patientyears that was within expected range for patients age  years and older and they received Repeated courses of rituximab were well tolerated in , patient-years with no additional safety concerns () .
Conclusion
e results obtained from this study, although done on a rather small number of RA patients, indicated that that Rituximab therapy is a safe for the number and structure of human chromosomes. After this study, we recommend further cytogenetic investigations for cytotoxicity using Brom-deoxiuridin in a blood cultures. Additional tests like micronucleus test (using Cytohalasin B) and analysis of binuclear lymphocytes could provide more information's if needed. Patients receiving cytotoxic drugs like Methotrexate and others should be screened for eventual chromosomal aberration in order to avoid cumulative drug cell toxicity. 
List of Abbreviations
